1887

Journal of Medical Microbiology logo

Volume 71, Issue 6

activity of fidaxomicin against nontuberculosis mycobacteria No Access

Abstract

Nontuberculous mycobacteria (NTM) infections are increasing worldwide and are relatively resistant to many of the first- and second-line drugs to treat tuberculosis. Macrolide antibiotics, such as clarithromycin and azithromycin, are the key drugs for treating NTM infections. Fidaxomicin is a macrolide antibiotic that is widely used in treating infections, and has high activity against especially multidrug-resistant tuberculosis (MDR-TB) and has no cross-resistance with rifampicin.

Fidaxomicin may have activity against NTM strains.

To find that whether the macrolide antibiotic fidaxomicin has activity against NTM strains.

Fidaxomicin used in this study was firstly tested on reference strains and has shown to be effective and workable. And then 28 rapidly growing mycobacteria (RGM), 12 slowly growing mycobacteria (SGM) reference strains and 103 NTM clinical isolates were tested by the microplate-based AlamarBlue assay (MABA) method to determine the MICs. Fidaxomicin, rifampicin and clarithromycin were tested against omplex subspecies 14 . and 5 . strains for inducible resistance determination.

In total, 21 out of 28 RGM and 9 of 12 SGM reference strains have the MICs of fidaxomicin at or below 1 µg ml. Fidaxomicin also showed low MIC values for some clinical isolates including complex, complex, , and . Fidaxomicin also has no inducible macrolide resistance in complex in comparison with clarithromycin.

Fidaxomicin has high activity against most of the NTM reference strains and some prevalent NTM clinical isolates. This promising finding warrants further investigation on the actions of fidaxomicn and as a potential antibiotic for NTM treatment.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): fidaxomicin , macrolides , MIC , nontuberculosis mycobacteria and rifampicin
© 2022 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001549
2022-06-16
2024-05-10
Loading full text...

Full text loading...

References

  1. Raju RM, Raju SM, Zhao Y, Rubin EJ. Leveraging Advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis 2016; 22:365–369 [View Article] [PubMed]
     [Google Scholar]
  2. Wang X, Li H, Jiang G, Zhao L, Ma Y et al. Prevalence and drug resistance of nontuberculous mycobacteria, northern China, 2008-2011. Emerg Infect Dis 2014; 20:1252–1253 [View Article] [PubMed]
     [Google Scholar]
  3. Yu X, Liu P, Liu G, Zhao L, Hu Y et al. The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis. J Infect 2016; 73:558–567 [View Article] [PubMed]
     [Google Scholar]
  4. Porvaznik I, Solovič I, Mokrý J. Non-tuberculous mycobacteria: classification, diagnostics, and therapy. Adv Exp Med Biol 2017; 944:19–25 [View Article] [PubMed]
     [Google Scholar]
  5. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416 [View Article] [PubMed]
     [Google Scholar]
  6. Venugopal AA, Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012; 54:568–574 [View Article] [PubMed]
     [Google Scholar]
  7. Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol 2020; 18:392–407 [View Article] [PubMed]
     [Google Scholar]
  8. Philley JV, DeGroote MA, Honda JR, Chan MM, Kasperbauer S et al. Treatment of non-tuberculous mycobacterial lung disease. Curr Treat Options Infect Dis 2016; 8:275–296 [View Article] [PubMed]
     [Google Scholar]
  9. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012; 15:149–161 [View Article] [PubMed]
     [Google Scholar]
  10. Kurabachew M, Lu SHJ, Krastel P, Schmitt EK, Suresh BL et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 2008; 62:713–719 [View Article] [PubMed]
     [Google Scholar]
  11. Sun Q, Wang S, Liao X, Jiang G, Huang H et al. Fidaxomicin has high in vitro activity against Mycobacterium tuberculosis. J Med Microbiol 2021; 70: [View Article] [PubMed]
     [Google Scholar]
  12. Boyaci H, Chen J, Lilic M, Palka M, Mooney RA et al. Fidaxomicin jams Mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contacts. Elife 2018; 7:e34823 [View Article] [PubMed]
     [Google Scholar]
  13. Molodtsov V, Scharf NT, Stefan MA, Garcia GA, Murakami KS. Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis. Mol Microbiol 2017; 103:1034–1045 [View Article] [PubMed]
     [Google Scholar]
  14. Blanchard JS. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu Rev Biochem 1996; 65:215–239 [View Article] [PubMed]
     [Google Scholar]
  15. Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) 2014; 3:317–340 [View Article] [PubMed]
     [Google Scholar]
  16. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647–650 [View Article] [PubMed]
     [Google Scholar]
  17. O’Neill A, Oliva B, Storey C, Hoyle A, Fishwick C et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:3163–3166 [View Article] [PubMed]
     [Google Scholar]
  18. Stout JE, Floto RA. Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others. Am J Respir Crit Care Med 2012; 186:822–823 [View Article] [PubMed]
     [Google Scholar]
  19. Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today 2018; 23:1502–1519 [View Article] [PubMed]
     [Google Scholar]
  20. Nie W, Duan H, Huang H, Lu Y, Chu N. Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculosis mycobacteria isolates. Biomed Res Int 2015; 2015:506598 [View Article] [PubMed]
     [Google Scholar]
  21. Kahlmeter G, Morris TE. EUCAST invite comments on new methods for antimicrobial susceptibility testing of anaerobic bacteria. Anaerobe 2021; 70:102417 [View Article] [PubMed]
     [Google Scholar]
  22. Cui Q-Q, Yang J, Niu Y-N, Qiang C-X, Li Z-R et al. Epidemiological investigation of Clostridioides difficile colonization in Chinese community infants. Anaerobe 2019; 56:116–123 [View Article] [PubMed]
     [Google Scholar]
  23. Cui Q-Q, Yang J, Sun S-J, Li Z-R, Qiang C-X et al. Carriage of Clostridioides difficile in healthy infants in the community of Handan, China: A 1-year follow-up study. Anaerobe 2021; 67:102295 [View Article] [PubMed]
     [Google Scholar]
  24. Kim SY, Kim C-K, Bae IK, Jeong SH, Yim J-J et al. The drug susceptibility profile and inducible resistance to macrolides of Mycobacterium abscessus and Mycobacterium massiliense in Korea. Diagn Microbiol Infect Dis 2015; 81:107–111 [View Article] [PubMed]
     [Google Scholar]
  25. Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother 2017; 72:376–384 [View Article] [PubMed]
     [Google Scholar]
  26. Dick T, Shin SJ, Koh WJ, Dartois V, Gengenbacher M. Rifabutin is active against Mycobacterium abscessus in Mice. Antimicrob Agents Chemother 2020; 64:e01943-19 [View Article] [PubMed]
     [Google Scholar]
  27. Aziz DB, Low JL, Wu M-L, Gengenbacher M, Teo JWP et al. Rifabutin is active against Mycobacterium abscessus complex. Antimicrob Agents Chemother 2017; 61:e00155-17 [View Article] [PubMed]
     [Google Scholar]
  28. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36:13–34 [View Article] [PubMed]
     [Google Scholar]
  29. Zhang Z, Lu J, Du Y, Xie F, Wang Y et al. Comparison of in vitro synergistic effect between clarithromycin or azithromycin in combination with amikacin against Mycobacterium intracellulare. J Glob Antimicrob Resist 2019; 18:183–186 [View Article] [PubMed]
     [Google Scholar]
  30. Adekambi T, Sassi M, van Ingen J, Drancourt M. Reinstating Mycobacterium massiliense and Mycobacterium bolletii as species of the Mycobacterium abscessus complex. Int J Syst Evol Microbiol 2017; 67:2726–2730 [View Article] [PubMed]
     [Google Scholar]
  31. Koh W-J, Jeon K, Lee NY, Kim B-J, Kook Y-H et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405–410 [View Article] [PubMed]
     [Google Scholar]
  32. Kim HS, Lee KS, Koh W-J, Jeon K, Lee EJ et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263:260–270 [View Article] [PubMed]
     [Google Scholar]
  33. Kim H-Y, Kim BJ, Kook Y, Yun Y-J, Shin JH et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54:347–353 [View Article] [PubMed]
     [Google Scholar]
  34. Stratton CW. Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003; 9:10–16 [View Article] [PubMed]
     [Google Scholar]
  35. Wise R. A review of the mechanisms of action and resistance of antimicrobial agents. Can Respir J 1999; 6 Suppl A:20A–2A [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001549
Loading
In vitro activity of fidaxomicin against nontuberculosis mycobacteria
J. Med. Microbiol. 71, 001549 (2022); https://doi.org/10.1099/jmm.0.001549
/content/journal/jmm/10.1099/jmm.0.001549
/content/journal/jmm/10.1099/jmm.0.001549
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error